Fexagratinib Drug Asset Due Diligence Report 2026

This Fexagratinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Fexagratinib can convert its Small molecule drug profile and FGFR1 x FGFR2 x FGFR3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fexagratinib (query alias: Fexagratinib)
Modality / target	Small molecule drug; FGFR1 x FGFR2 x FGFR3; FGFR1 antagonists, FGFR2 antagonists, FGFR3 antagonists
Highest global status	Phase 2
Originator	AstraZeneca PLC
Active developers	AstraZeneca PLC, Wuxi Heyu Biomedical Technology Co., Ltd., Abbisko Therapeutics Co., Ltd.

The MCP disease footprint includes Locally Advanced Urothelial Carcinoma, Metastatic urothelial carcinoma, Metastatic breast cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05775874	Phase 2	Unknown status	80	Primary endpoint not disclosed in English source
NCT05533788	Phase 1	Completed	13	Primary endpoint not disclosed in English source
CTR20221342	Not Applicable	Not yet recruiting	16	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations.

Phase 1/2; n=32; evaluation: Positive. Reported fields: ORR = 34.4 % (95%CI, 18.6 - 53.2); PR = 37.0 %

Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).

Phase 2; n=26; evaluation: Positive. Reported fields: ORR(FGFR3 overexpression but without mutation/fusion) = 37.5 % (95%CI )

CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA

Phase 1/2; n=12; evaluation: Negative. Reported fields: PFS6 = 25 % ( 5 - 57)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fexagratinib addresses Locally Advanced Urothelial Carcinoma, Metastatic urothelial carcinoma, Metastatic breast cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-04-29	Transaction title not available in English source	Phase 1/2	Financial terms not disclosed
2019-11-06	Transaction title not available in English source	Phase 1/2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of drug combination composition in preparation of drugs for treating solid tumors”. The milestone feed surfaced a patent-application signal described as “Methods and materials for generating stem cell-derived endocrine cell types”. The milestone feed surfaced a patent-application signal described as “Method for identifying personalized therapeutic strategies for patients affected with a cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO